Twitxy Saved

Bowen Jing

Verified account This account is verified. Learn more

@bjing2016

AI x drug discovery | Head of ML @ Divergence Labs | PhD '26 @MIT
bjing2016.github.io Joined February 2024
652 Following 3.3K Followers 53 Posts

Latest posts 5

Pinned post

Bowen Jing Verified account @bjing2016
Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude.

At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells.

Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI.

We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force.

Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.
0:15
133 replies 630 reposts 5.1K likes 511K views View on X
Bowen Jing Verified account @bjing2016
After almost four months, Mol-1 has officially dethroned OpenDDE to become the #1 open-weight antibody foundation model on cofoldarena.ai. Congrats @jiarlu and @MolenceBio team!

All predictions are available to view and download.
Molence Verified account @MolenceBio Oct 27
Introducing Mol-1: Open Frontier Biomolecular Intelligence 🚀🚀🚀
📊 75.0% on FoldBench-AB, near IsoDDE's reported 75.58%!!!
🧬 60k-token assemblies on one single H20, outperforming Anthropic 8/10.
🎯 VHHs binding hit rate as high as 63% with best SPR KD at 43 pM.

GitHub: github.com/molence/Mol-1
Try it: lab.molence.com
View quoted post on X
5 replies 14 reposts 128 likes 6.4K views View on X
Bowen Jing Verified account @bjing2016
Our recent work on Claude-designed anti-IgE antibodies for food allergy was spearheaded by the brilliant @EErives40101 and @ferrara_em76515, follow them for potential future updates!
Ezra Erives Verified account @EErives40101 Oct 28
In collaboration with Anthropic, we recently announced promising initial progress toward the computational design of a biparatopic disruptive IgE inhibitor for food allergy, a condition affecting upwards of 200 million people worldwide.

The current standard of care, omalizumab (Xolair), acts by sequestering free immunoglobulin E (IgE), preventing it from binding its high-affinity receptor FcεRI on mast cells and basophils, cross-linking in the presence of allergen, and triggering anaphylaxis. However, omalizumab’s inability to disrupt pre-existing receptor-bound IgE leaves many patients highly reactive and presents an urgent and unmet need.

Significant effort has therefore been directed toward the development and characterization of disruptive IgE inhibitors, which additionally drive the dissociation of receptor-bound IgE. The most potent such disruptive inhibitors are biparatopics: two “arm" molecules linked together into a single construct whose avid binding to the bound complex realizes the desired disruptive effect at significantly lower, and ideally therapeutically viable, concentrations.

We reasoned that the precise geometric specifications required of such a construct made it a promising target for computational design, and with the help of Claude, our research team at Divergence Labs undertook a computational design campaign toward this end, designing and experimentally validating several viable arms that we are presently combining into a full biparatopic.

While this work is neither a complete discovery campaign nor even the full extent of the proposed computational campaign, we believe it highlights the strength of molecular design in enabling the rapid discovery of binders with diverse geometric and kinetic profiles, both key to the function of derived multispecifics. The ability to do so at low cost in time and capital, and in a geometrically aware fashion, stands as a valuable complement to immunization, high-throughput display, and other means of screening at scale.

For more, check out Anthropic’s blog post below, and our technical report here: divergencelabs.com/publications/i…. (1/2)
View quoted post on X
2 replies 1 reposts 34 likes 2.1K views View on X
Bowen Jing Verified account @bjing2016
Super exciting to see the $1.8B commitment to data collection towards the virtual cell led by @biohub @alexrives ! The best direction to take this investment IMO is to scale up (no pun intended) Thousandfold Expansion Microscopy from @eboyden3 @AliHShaib, enabling in situ, nm-resolution imaging of individual molecules in intact cells with simple light microscopy.

Imagine blowing up a cell to the size of a marble and studying the identity, interactions, and even conformations of every individual macromolecule in a diseased tissue. This kind of full state observability will go a long way to closing the gap between observational and causal understanding (not to mention generating petabytes of high-SNR data for AI models).
Ali H. Shaib Verified account @AliHShaib Jun 1
Hello world, meet 1,000× Expansion Microscopy.
1,000,000,000× expansion by volume! A gel that starts at a few centimeters will then expand to the volume of an Olympic swimming pool. biorxiv.org/content/10.648…
In our new bioRxiv preprint, work carried out between MIT and UMG, led by Helena Hu in collaboration with scientists from the labs of @eboyden3 Ed Boyden, Silvio Rizzoli, and myself, we present Thousandfold Expansion Microscopy.
By enlarging biological specimens across multiple rounds of expansion, molecular-scale features, as small as the distances between adjacent amino acids, can be visualized with conventional optical microscopes.
Democratizing super-resolution microscopy.
View quoted post on X
7 replies 14 reposts 127 likes 14K views View on X
Bowen Jing Verified account @bjing2016
Claude’s protein design results give insight into whether differences in success rates can be explained by structural confidence, or if there are latent factors. The evidence seems to favor the latter, suggesting that method improvements will remain challenging to judge in silico
Anthropic Verified account @AnthropicAI Aug 18
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work.

We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets.

We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
View quoted post on X